Lupin Limited — Updates, 08-05-2025: Press Release

Lupin has announced a board meeting on the financial results for the quarter and half-year. The company secured U.S. FDA approval for Raltegravir Tablets USP, 600 mg, gaining 180 days of generic exclusivity. This product, with estimated annual U.S. sales of USD 34 million, will be manufactured at Lupin’s Nagpur facility, boosting its presence in the U.S. antiretroviral market and strengthening its portfolio in HIV therapies.